Long-term safety of sapropterin in paediatric and adult individuals with phenylalanine hydroxylase deficiency: Final results of the Kuvan® Adult Maternal Paediatric European Registry multinational observational study.
BH4
KAMPER
hyperphenylalaninaemia
phenylalanine hydroxylase deficiency
phenylketonuria
sapropterin dihydrochloride
Journal
Journal of inherited metabolic disease
ISSN: 1573-2665
Titre abrégé: J Inherit Metab Dis
Pays: United States
ID NLM: 7910918
Informations de publication
Date de publication:
05 Sep 2024
05 Sep 2024
Historique:
revised:
08
08
2024
received:
20
12
2023
accepted:
22
08
2024
medline:
6
9
2024
pubmed:
6
9
2024
entrez:
5
9
2024
Statut:
aheadofprint
Résumé
Phenylketonuria is a rare inherited disorder that disrupts the metabolism of phenylalanine (Phe) to tyrosine by phenylalanine hydroxylase (PAH). Sapropterin dihydrochloride (Kuvan®) is approved for use in Europe to reduce blood Phe levels and improve Phe tolerance in sapropterin-responsive individuals. KAMPER (NCT01016392) is an observational, multinational registry assessing long-term safety and efficacy of sapropterin. Five hundred and seventy-six participants with PAH deficiency were enrolled from nine European countries (69 sites; December 2009-May 2016). Participants were aged <4 years (n = 11), 4 to <12 years (n = 329), 12 to <18 years (n = 141), and ≥18 years (n = 95) at enrolment. Overall, 401 (69.6%) participants experienced a total of 1960 adverse events; 61 events in 42 participants were serious, and two were considered sapropterin-related by the investigator. Mean (standard deviation) actual dietary Phe intake increased from baseline across all age groups: 957 (799) mg/day to a maximum of 1959 (1121) mg/day over a total study period of 11 years. Most participants exhibited an increase in Phe tolerance while blood Phe levels remained in the target range for their age (120-360 μmol/L for <12 years; 120-600 μmol/L for ≥12 years). Most participants exhibited normal growth for height, weight, and body mass index. No additional safety concerns were identified. As an observational study, limitations include variability in routine care practices and inconsistent availability of data. Long-term sapropterin use demonstrates a favourable safety profile in real-world settings and increases Phe tolerance in participants with PAH deficiency while maintaining blood Phe levels in the target ranges.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : BioMarin Pharmaceutical
Informations de copyright
© 2024 The Author(s). Journal of Inherited Metabolic Disease published by John Wiley & Sons Ltd on behalf of SSIEM.
Références
van Spronsen FJ, Blau N, Harding C, Burlina A, Longo N, Bosch AM. Phenylketonuria. Nat Rev Dis Primers. 2021;7(1):36.
van Wegberg AMJ, MacDonald A, Ahring K, et al. The complete European guidelines on phenylketonuria: diagnosis and treatment. Orphanet J Rare Dis. 2017;12(1):162.
Blau N, van Spronsen FJ, Levy HL. Phenylketonuria. Lancet. 2010;376(9750):1417‐1427.
Vockley J, Andersson HC, Antshel KM, et al. Phenylalanine hydroxylase deficiency: diagnosis and management guideline. Genet Med. 2014;16(2):188‐200.
Bilder DA, Kobori JA, Cohen‐Pfeffer JL, Johnson EM, Jurecki ER, Grant ML. Neuropsychiatric comorbidities in adults with phenylketonuria: a retrospective cohort study. Mol Genet Metab. 2017;121(1):1‐8.
Enns GM, Koch R, Brumm V, Blakely E, Suter R, Jurecki E. Suboptimal outcomes in patients with PKU treated early with diet alone: revisiting the evidence. Mol Genet Metab. 2010;101(2–3):99‐109.
Macleod EL, Ney DM. Nutritional management of phenylketonuria. Ann Nestle Eng. 2010;68(2):58‐69.
Walter JH, White FJ, Hall SK, et al. How practical are recommendations for dietary control in phenylketonuria? Lancet. 2002;360(9326):55‐57.
European Medicines Agency. Sapropterin dihydrochloride (Kuvan) summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/kuvan-epar-product-information_en.pdf. Accessed 19 January 2023
van Spronsen FJ, van Wegberg AM, Ahring K, et al. Key European guidelines for the diagnosis and management of patients with phenylketonuria. Lancet Diabetes Endocrinol. 2017;5(9):743‐756.
Trefz FK, Burton BK, Longo N, et al. Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double‐blind, placebo‐controlled study. J Pediatr. 2009;154(5):700‐707.
Trefz FK, Muntau AC, Lagler FB, et al. The Kuvan(®) Adult Maternal Paediatric European Registry (KAMPER) multinational observational study: baseline and 1‐year data in phenylketonuria patients responsive to sapropterin. JIMD Rep. 2015;23:35‐43.
Feillet F, Ficicioglu C, Lagler FB, et al. Efficacy and safety of sapropterin before and during pregnancy: final analysis of the Kuvan® Adult Maternal Paediatric European Registry (KAMPER) maternal and phenylketonuria developmental outcomes and safety (PKUDOS) PKU‐MOMs sub‐registries. J Inherit Metab Dis. 2024;47(4):636‐650.
Lennon EM, Gardner JM, Karmel BZ, Flory MJ. Bayley scales of infant development. In: Haith MM, Benson JB, eds. Encyclopedia of Infant and Early Childhood Development. Academic Press; 2008:145‐156.
Frankenburg WK, Dodds J, Archer P, Shapiro H, Bresnick B. The Denver II: a major revision and restandardization of the Denver developmental screening test. Pediatrics. 1992;89(1):91‐97.
World Health Organization. Growth reference data for 5–19 years. https://www.who.int/tools/growth-reference-data-for-5to19-years. Accessed 19 January 2023
World Health Organization. Child growth standards. https://www.who.int/tools/child-growth-standards. Accessed 19 January 2023
Longo N, Arnold GL, Pridjian G, et al. Long‐term safety and efficacy of sapropterin: the PKUDOS registry experience. Mol Genet Metab. 2015;114(4):557‐563.
Muntau AC, Burlina A, Eyskens F, et al. Long‐term efficacy and safety of sapropterin in patients who initiated sapropterin at <4 years of age with phenylketonuria: results of the 3‐year extension of the SPARK open‐label, multicentre, randomised phase IIIb trial. Orphanet J Rare Dis. 2021;16(1):341.
Qu J, Yang T, Wang E, et al. Efficacy and safety of sapropterin dihydrochloride in patients with phenylketonuria: a meta‐analysis of randomized controlled trials. Br J Clin Pharmacol. 2019;85(5):893‐899.
Campistol J, Gassió R, Artuch R, Vilaseca MA, PKU Follow‐up Unit. Neurocognitive function in mild hyperphenylalaninemia. Dev Med Child Neurol. 2011;53(5):405‐408.
European Commission. Support for children with special educational needs (SEN). https://ec.europa.eu/social/BlobServlet?docId=15993&langId=en. Accessed 19 January 2023
European Commission, European Education and Culture Executive Agency, Almeida Coutinho AS, Borodankova O. Grade Retention during Compulsory Education in Europe – Regulations and Statistics. doi:10.2797/50570 Accessed 14 June 2024.
Anikster Y, Haack TB, Vilboux T, et al. Biallelic mutations in DNAJC12 cause hyperphenylalaninemia, dystonia, and intellectual disability. Am J Hum Genet. 2017;100(2):257‐266.